Cargando…

Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine

This study aimed to formulate and evaluate a floating raft system for the co-delivery of etoricoxib (ETO) and famotidine (FAM) using a combination of glucomannan with natural/semi-synthetic polysaccharides. Formulation variables affect gelation lag time (GLT), floating lag time (FLT), and release pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoman, Nabil A., Saady, Marwa, Teaima, Mahmoud, Abdelmonem, Rehab, El-Nabarawi, Mohamed A., Elhabal, Sammar Fathy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184610/
https://www.ncbi.nlm.nih.gov/pubmed/36927148
http://dx.doi.org/10.1080/10717544.2023.2189630
_version_ 1785042180127064064
author Shoman, Nabil A.
Saady, Marwa
Teaima, Mahmoud
Abdelmonem, Rehab
El-Nabarawi, Mohamed A.
Elhabal, Sammar Fathy
author_facet Shoman, Nabil A.
Saady, Marwa
Teaima, Mahmoud
Abdelmonem, Rehab
El-Nabarawi, Mohamed A.
Elhabal, Sammar Fathy
author_sort Shoman, Nabil A.
collection PubMed
description This study aimed to formulate and evaluate a floating raft system for the co-delivery of etoricoxib (ETO) and famotidine (FAM) using a combination of glucomannan with natural/semi-synthetic polysaccharides. Formulation variables affect gelation lag time (GLT), floating lag time (FLT), and release percentage of drugs after 1–8 h, Stability, and viscosity parameters were evaluated. In vivo X-ray studies, followed by the pharmacokinetic study, were performed on human volunteers. Formulations exhibited pseudoplastic behavior for ease of swallowing. The optimum raft system (ORS) comprised 1% Na alginate, 0.1% Low Methoxyl (LM) pectin, 0.8% Konjac glucomannan (KGL), 1% Precirol, and 1% CaCO(3). ORS exhibited rapid GLT and FLT (around 42 and 8 sec respectively) in 0.1 N HCl as well as controlled release of ETO (15% in 1 h and 82% in 8 h) and FAM (29% in 1 h and 85% in 8 h). Formulation stability with the absence of any drug-excipient interactions was observed. The X-ray imaging showed a promising buoyancy ability for approximately 8 h. Compared with marketed products, ORS showed superior relative bioavailability for both drugs. These findings revealed the successful preparation of a promising raft system with improved dual drug delivery.
format Online
Article
Text
id pubmed-10184610
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-101846102023-05-16 Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine Shoman, Nabil A. Saady, Marwa Teaima, Mahmoud Abdelmonem, Rehab El-Nabarawi, Mohamed A. Elhabal, Sammar Fathy Drug Deliv Research Article This study aimed to formulate and evaluate a floating raft system for the co-delivery of etoricoxib (ETO) and famotidine (FAM) using a combination of glucomannan with natural/semi-synthetic polysaccharides. Formulation variables affect gelation lag time (GLT), floating lag time (FLT), and release percentage of drugs after 1–8 h, Stability, and viscosity parameters were evaluated. In vivo X-ray studies, followed by the pharmacokinetic study, were performed on human volunteers. Formulations exhibited pseudoplastic behavior for ease of swallowing. The optimum raft system (ORS) comprised 1% Na alginate, 0.1% Low Methoxyl (LM) pectin, 0.8% Konjac glucomannan (KGL), 1% Precirol, and 1% CaCO(3). ORS exhibited rapid GLT and FLT (around 42 and 8 sec respectively) in 0.1 N HCl as well as controlled release of ETO (15% in 1 h and 82% in 8 h) and FAM (29% in 1 h and 85% in 8 h). Formulation stability with the absence of any drug-excipient interactions was observed. The X-ray imaging showed a promising buoyancy ability for approximately 8 h. Compared with marketed products, ORS showed superior relative bioavailability for both drugs. These findings revealed the successful preparation of a promising raft system with improved dual drug delivery. Taylor & Francis 2023-03-17 /pmc/articles/PMC10184610/ /pubmed/36927148 http://dx.doi.org/10.1080/10717544.2023.2189630 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Research Article
Shoman, Nabil A.
Saady, Marwa
Teaima, Mahmoud
Abdelmonem, Rehab
El-Nabarawi, Mohamed A.
Elhabal, Sammar Fathy
Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine
title Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine
title_full Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine
title_fullStr Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine
title_full_unstemmed Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine
title_short Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine
title_sort merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184610/
https://www.ncbi.nlm.nih.gov/pubmed/36927148
http://dx.doi.org/10.1080/10717544.2023.2189630
work_keys_str_mv AT shomannabila mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine
AT saadymarwa mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine
AT teaimamahmoud mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine
AT abdelmonemrehab mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine
AT elnabarawimohameda mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine
AT elhabalsammarfathy mergingkonjacglucomannanwithothercopolymerichydrogelsasacuttingedgeliquidraftsystemfordualdeliveryofetoricoxibandfamotidine